In immunotherapy of cancer, the use of blocking anti–CTLA-4 and anti–PD-1 antibodies have yielded promising results, and the 2018 Nobel Prize was granted to Jim P. Allison and Tasuku Honjo, who are the pioneers in this field (Wolchok, 2018). This evidence concerns the gene PDCD1 and cancer.